Home › NDC Lookup › RxCUI directory › RxCUI 2639957

5.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Injection [Vyvgar... — RxCUI 2639957

RxNorm drug concept · Semantic branded drug
RxCUI 2639957 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2639957
Official name5.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Injection [Vyvgart Hytrulo]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVyvgart Hytrulo 1008 MG / 11,200 UNT per 5.6 ML Injection; VYVGART Hytrulo 1008 MG / 11,200 UNT in 5.6 ML Injection; Vyvgart Hytrulo (efgartigimod alfa-hyaluronidase-qvfc 1008 MG / 11,200 UNT) per 5.6 ML Injection
FDA products mapped2
Package NDCs mapped3
Reported Medicaid activity (SDUD)2,063 prescriptions · 26 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How 5.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyalur... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 5.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Injection [Vyvgart Hytrulo] RxCUI 2639957

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Efgartigimod alfa 2587717
    • Hyaluronidase 5464
    • Efgartigimod alfa / hyaluronidase 2639948
    • Efgartigimod alfa-qvfc 2639944
    • Hyaluronidase-qvfc 2639946
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vyvgart Hytrulo 2639953
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Efgartigimod alfa / hyaluronidase Injection 2639950
    • Efgartigimod alfa-qvfc / hyaluronidase-qvfc Injection 2646055
    • Efgartigimod alfa / hyaluronidase Injectable Product 2639949
    • Efgartigimod alfa-qvfc / hyaluronidase-qvfc Injectable Product 2662922
    • Efgartigimod alfa / hyaluronidase Injection [Vyvgart Hytrulo] 2639956
    • Efgartigimod alfa-qvfc / hyaluronidase-qvfc Injection [Vyvgart Hytrulo] 2655799
    • Vyvgart Hytrulo Injectable Product 2639955
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 5.6 ML efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML Injection SCD · 2639951
  • Efgartigimod alfa-qvfc 180 MG/ML SCDC · 2639945
  • Hyaluronidase-qvfc 2000 UNT/ML SCDC · 2639947
  • Efgartigimod alfa / hyaluronidase Injection SCDF · 2639950
  • Efgartigimod alfa-qvfc / hyaluronidase-qvfc Injection SCDFP · 2646055
  • Efgartigimod alfa / hyaluronidase Injectable Product SCDG · 2639949
  • Efgartigimod alfa-qvfc / hyaluronidase-qvfc Injectable Product SCDGP · 2662922

Brand-Name Concepts

  • Efgartigimod alfa-qvfc 180 MG/ML / hyaluronidase-qvfc 2000 UNT/ML [Vyvgart Hytrulo] SBDC · 2639954
  • Efgartigimod alfa / hyaluronidase Injection [Vyvgart Hytrulo] SBDF · 2639956
  • Efgartigimod alfa-qvfc / hyaluronidase-qvfc Injection [Vyvgart Hytrulo] SBDFP · 2655799
  • Vyvgart Hytrulo Injectable Product SBDG · 2639955
  • Vyvgart Hytrulo BN · 2639953

📦 FDA Products & Package NDCs

2 products · 3 package NDCs
3 package NDCs map to RxCUI 2639957 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73475-1221-01 1 SYRINGE, GLASS in 1 CARTON (73475-1221-1) / 5 mL in 1 SYR... VYVGART Hytrulo argenx US 2025-04-10
73475-1221-04 4 SYRINGE, GLASS in 1 CARTON (73475-1221-4) / 5 mL in 1 SYR... VYVGART Hytrulo argenx US 2025-04-10
73475-3102-03 1 VIAL, SINGLE-DOSE in 1 CARTON (73475-3102-3) / 5.6 mL in... VYVGART Hytrulo argenx US 2023-06-20
Observed labelers: argenx US (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9334 Inj efgart-alfa 2mg hya-qvfc 3 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.